How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,677 results for

Thyroid Function Summary

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors

: Recruiting First Posted : December 4, 2017 Last Update Posted : April 11, 2018 See Sponsor: University of Chicago Information provided by (Responsible Party): University of Chicago Study Details Study Description Go to Brief Summary: Phase II, 2-cohort, single arm trial treated with the combination of the following two agents: Pembrolizumab (MK3475) 200mg, every three weeks, iv Docetaxel 75mg/m2, every three weeks, iv Condition or disease Intervention/treatment Phase Thyroid Cancer Salivary Gland Cancer (...) Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

122. Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases

Posted : September 11, 2017 See Sponsor: Assiut University Information provided by (Responsible Party): Sara Elewa Ahmed, Assiut University Study Details Study Description Go to Brief Summary: Early diagnosis of thyroid and lipid disorders by regular screening, and treatment of such disorders in CKD patients may be highly beneficial to slow progression of CKD. The study will be conducted to investigate thyroid function and lipid profile in patients with chronic kidney disease. Condition or disease (...) with a number of serious complications, including increased incidence of cardiovascular disease, hyperlipidemia, anemia and metabolic bone disease .CKD patients should be assessed for the presence of these complications and receive optimal treatment to reduce their morbidity and mortality . CKD affects thyroid function in many ways, including low thyroid circulating hormone levels, altered peripheral hormone metabolism, insufficient binding to carrier proteins, reduced tissue thyroid hormone content

2017 Clinical Trials

123. Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean

2017 Clinical Trials

124. Nivolumab Plus Ipilimumab in Thyroid Cancer

provided by (Responsible Party): Jochen Lorch, MD, Dana-Farber Cancer Institute Study Details Study Description Go to Brief Summary: This research study is studying nivolumab, an investigational drug, in combination with ipilimumab, also an investigational drug, as a possible treatment for thyroid cancer. The drugs involved in this study are: Nivolumab (Opdivo™) Ipilimumab (Yervoy™) Condition or disease Intervention/treatment Phase Thyroid Cancer Drug: Nivolumab Drug: Ipilimumab Phase 2 Detailed (...) kinase inhibitor (TKI) failure and progression within 13 months prior to enrollment (10 patients) and anaplastic thyroid cancer (7 patients) Any number of lines of prior treatment are allowed Any line of prior treatment for patients under 65y, over 65y must have at least one prior line of TKI treatment Age 18 years or older ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) Participants must have normal organ and marrow function as defined below: Screening laboratory values must meet

2017 Clinical Trials

125. The Efficacy of Intermediate Cervical Plexus Block Versus Cutaneous and Thyroid Capsular Blocks

First Posted : September 1, 2017 Last Update Posted : October 11, 2017 See Sponsor: Mansoura University Information provided by (Responsible Party): Mansoura University Study Details Study Description Go to Brief Summary: Thyroid gland surgery is one of the most commonly performed operations for either benign or malignant pathologies Pain related to thyroid surgery is of moderate intensity .which may be treated with NSAIDs or opioids. However, Opioids have many well-known undesirable effects (...) table for eligibility information Ages Eligible for Study: 20 Years to 60 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: American Society of Anesthesiologists physical status grade I and grade II. Euthyroidism after thyroid function tests Exclusion Criteria: Patient refusal. Thyroid gland more than 5 cm size. Retrosternal extension. Planned block neck dissection. Neuromuscular diseases Hematological diseases. Bleeding diseases. Coagulation

2017 Clinical Trials

126. Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer

Estimated Study Completion Date : December 31, 2026 Resource links provided by the National Library of Medicine related topics: available for: resources: Groups and Cohorts Go to Group/Cohort Active surveillance Patients under active surveillance choose to not have immediate thyroidectomy. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (...) Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2017 Clinical Trials

127. Myeloid Cell Reprogramming in Thyroid Carcinoma

): Radboud University Study Details Study Description Go to Brief Summary: This study investigates the reprogramming of myeloid cells in patients with thyroid carcinoma. The investigators hypothesize that tumor-derived factors change the function of myeloid cells in such a way that these immune cells promote tumor growth rather than combat the tumor. Condition or disease Thyroid Cancer Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 50 participants (...) Myeloid Cell Reprogramming in Thyroid Carcinoma Myeloid Cell Reprogramming in Thyroid Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Myeloid Cell Reprogramming in Thyroid Carcinoma The safety

2017 Clinical Trials

128. Potential Preventive Effect of Selenium on Iodine-induced Thyroid Autoimmunity During Pregnancy

without particular iodine supplementation. Participants are asked to complete a questionnaire on dietary habits concerning iodine. Thyroid function (thyroid-stimulating hormone, free thyroxine) and thyroperoxidase antibodies (TPO-Ab) and urinary iodine are measured during first, second and third trimester of pregnancy and week 8 after delivery in both, intervention and control group. Condition or disease Intervention/treatment Phase Pregnancy Thyroid Autoimmune Disease Iodine Deficiency Selenium (...) Potential Preventive Effect of Selenium on Iodine-induced Thyroid Autoimmunity During Pregnancy Potential Preventive Effect of Selenium on Iodine-induced Thyroid Autoimmunity During Pregnancy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

129. Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Update Posted : March 20, 2019 See Sponsor: Peking Union Medical College Hospital Information provided by (Responsible Party): Yansong Lin, Peking Union Medical College Hospital Study Details Study Description Go to Brief Summary: Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) is a great challenge in the treatment of thyroid cancer. Tyrosine kinase inhibitors (TKIs), like sorafenib and lenvatinib which have been approved by food and drug administration (FDA), could (...) Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2017 Clinical Trials

130. Thyroid in Bariatric Surgery

Description Go to Brief Summary: This study is expected to provide novel data regarding potential structural and functional changes of the thyroid gland in morbidly obese adults following significant weight loss through bariatric surgery. These data will complement evidence from epidemiological studies regarding the association of obesity and alterations in thyroid function. Potentially this study may justify further longer-term studies regarding the effects of weight gain and/or weight loss (...) on the morphology of the thyroid gland and could help to form recommendations regarding follow-up investigations for the thyroid in morbidly obese patients. Condition or disease Intervention/treatment Phase Thyroid Obesity Insulin Resistance Autoimmune Thyroiditis Procedure: Bariatric surgery Not Applicable Detailed Description: Alterations in thyroid function are reported in obesity. Thyroid hormones and thyroid-stimulating hormone (TSH) concentrations have been variously described as normal, elevated, or low

2017 Clinical Trials

131. The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure

health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03064542 Recruitment Status : Recruiting First Posted : February 27, 2017 Last Update Posted : August 23, 2017 See Sponsor: Clinical Nutrition Research Centre, Singapore Collaborator: Agency for Science, Technology and Research Information provided by (Responsible Party): Melvin Leow, Tan Tock Seng Hospital Study Details Study Description Go to Brief Summary: To determine how thyroid status regulates (...) clinic at TTSH, the doctors will review that result and decide if a repeat test is needed. If subjects are confirmed by blood tests to have Graves' disease type of hyperthyroidism, they are eligible to take part in this study. However, approximately 2 teaspoons (~ 10 mL) of blood will be taken for baseline thyroid function test just prior to the initiation of anti-thyroid drugs. Pre-menopausal women will also undergo a urine pregnancy test to exclude pregnancy prior to participation at study entry

2017 Clinical Trials

132. Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF)

within the past 2 weeks. Scheduled cardiac resynchronization therapy or heart transplantation. History of malignant tumor or life expectancy under 12 months. Already on medications that may affect thyroid function (L-T4, carbimazole, propylthiouracil, amiodarone, lithium). Pregnancy and lactation period. Participation in another clinical trial within the past 30 days. Contraindication or intolerance to evidence-based therapy for CHF, such as beta-blocker, angiotensin-converting enzyme inhibitor (...) Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF) Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2017 Clinical Trials

133. Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

(NCI) Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ) Study Details Study Description Go to Brief Summary: Background: Medullary thyroid cancer (MTC) is a tumor of the thyroid gland. Surgery is the only current treatment to cure it. The drug pembrolizumab (MK-3475) is a new type of cancer therapy. It works by allowing the immune system to detect and kill tumor cells. Objective: To test how pembrolizumab affects (...) Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pembrolizumab in Recurrent

2017 Clinical Trials

134. Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.

: Recruiting First Posted : April 25, 2017 Last Update Posted : May 4, 2017 See Sponsor: Jena University Hospital Collaborator: GE Healthcare Information provided by (Responsible Party): Jena University Hospital Study Details Study Description Go to Brief Summary: Regular thyroid diagnostics versus augmented thyroid work-up with additional I-124 PET/US fusion for metabolic-sonographic nodule allocation in patients with benign thyroid diseases Condition or disease Intervention/treatment Thyroid Nodule (...) to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography. Regular Thyroid Work-up and I-124 PET/US Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics and additional I-124 PET/CT, followed by I-124 PET/US (administration of I-124 was not subject of this study). Data and images of patient characteristics, laboratory results, ultrasonography loops, planar 99mTcO4 scintigraphy as well as I-124

2017 Clinical Trials

135. A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Sponsor: Dana-Farber Cancer Institute Collaborator: Genentech, Inc. Information provided by (Responsible Party): Mark Awad, MD, Dana-Farber Cancer Institute Study Details Study Description Go to Brief Summary: This research trial is studying a drug called alectinib as a possible treatment for non-small cell lung cancer (NSCLC) with specific genetic alterations known as ALK or RET rearrangements, and thyroid cancer with RET rearrangements. Condition or disease Intervention/treatment Phase ALK-positive (...) A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

136. Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03085056 Recruitment Status : Recruiting First Posted : March 21

2017 Clinical Trials

137. Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer

Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2017 Clinical Trials

138. UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

to Brief Summary: This is a Phase 2 Study of Everolimus and Lenvatinib in patients with metastatic differentiated thyroid cancer who have progressed on lenvatinib alone. Patient will have imaging, lab test and physical exams Condition or disease Intervention/treatment Phase Thyroid Cancer Drug: Lenvatinib Drug: Everolimus Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 40 participants Intervention Model: Single Group (...) UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search

2017 Clinical Trials

139. Thyroid Dysfunction in Patients With Type 2 Diabetes With Early Diabetic Nephropathy.

, there was curiosity to understand and learn the association of this disorder with another common endocrine gland function that is thyroid gland . The association between these two disorders has long been recognized although the prevalence of thyroid dysfunction in diabetic population varies widely between studies. With insulin and thyroid hormone being intimately involved in cellular metabolism and thus excess or deficit of these hormones result in functional derangement of the other . Diabetic patients have (...) factor for development of diabetic nephropathy. Condition or disease Evaluation Thyroid Functions in Diabetic Patient Detailed Description: Recognition and treatment of thyroid dysfunction in diabetic patients will benefit glycemic control and improve general well-being Diabetic nephropathy, a major microvascular complication of type 2 diabetes mellitus, is an important cause of chronic kidney disease. It results from interactions between hemodynamic and metabolic factors. Study Design Go to Layout

2017 Clinical Trials

140. Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>